Drug intelligence / Profile preview

DT2219ARL

Development stage: Phase 2
Lead developer: GT Biopharma
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DT2219ARL is a novel bispecific ligand-directed toxin (BLT) consisting of two single-chain variable fragments (scFv) recognizing human CD19 and CD22 linked to the first 389 amino acids of diphtheria toxin (DT390). It targets cancer cells expressing the CD19 receptor, CD22 receptor, or both receptors. When DT2219ARL binds to cancer cells, they internalize the drug and are killed due to the action of the drug's cytotoxic payload. The drug has demonstrated potency in the IC50s 0.06–0.2 nM range and has shown success in early human clinical trials for patients with relapsed/refractory B-cell lymphoma or leukemia.

Other names: Anti-CD19/anti-CD22 bispecific immunotoxin DT2219ARL

Targets

CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on DT2219ARL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DT2219ARL.

Explore the full profile